Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enveric Biosciences Inc
(NQ:
ENVB
)
0.4901
+0.0001 (+0.02%)
Streaming Delayed Price
Updated: 1:01 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Enveric Biosciences Inc
< Previous
1
2
3
Next >
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
October 11, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
October 03, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
September 27, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Inc. (NASDAQ: ENVB) Leading the Way in Wednesday Trading Based on Percentage Gain
May 24, 2023
Via
Investor Brand Network
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
September 20, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
September 18, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
September 11, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
September 05, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
August 30, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
August 28, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
August 21, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
August 14, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373
July 24, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
July 17, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing
June 26, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
June 12, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
June 07, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
June 05, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
May 30, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
May 24, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
May 22, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
May 19, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Inc. (NASDAQ: ENVB) is One of Thursday Morning’s Most Active Stocks
May 18, 2023
Via
Investor Brand Network
Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373
May 18, 2023
Enveric Biosciences, Inc. (NASDAQ: ENVB) is engaged as a biotechnology company, which focused on the research and development of innovative
Via
Spotlight Growth
Topics
Derivatives
Intellectual Property
Exposures
Derivatives
Intellectual Property
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
May 18, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month
May 02, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
April 10, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
April 03, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
March 23, 2023
From
Enveric Biosciences
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.